A Pharmacogenetic Approach to Parkinson’s Disease

A 2017 Penn Center for Precision Medicine Accelerator Fund recipient, Alice Chen-Plotkin, MD, describes her lab’s development of precision genetic profiling tools to detect individuals susceptible to loss of impulse control during Parkinson’s therapy, a side-effect that affects 20% of treated patients. Dr Chen-Plotkin is an Associate Professor of Neurology at Penn Medicine.

Related Links

Personalized Diagnostics for Hematologic and Solid Tumor Cancers

Visit the Chen-Plotkin Lab


July 19, 2017

Created by

Penn Physician VideoLink